Conference Coverage

This year, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature a breadth of new data on emerging antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), particularly across solid tumors and hematologic malignancies. This article synthesizes pivotal findings from AbbVie’s next-generation ADC and TCE platforms—including SEZ6-, PSMA/STEAP1-, c-Met-, and FRα-targeted ADCs—alongside immune checkpoint inhibitor combinations and real-world evidence.

AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1)

The field of antibody-drug conjugates (ADCs) and bispecific antibody-drug conjugates (bsADCs) is rapidly expanding, offering new hope for the treatment of a range of solid tumors with high unmet medical need. Recent abstracts from the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA, highlight several promising technological and therapeutic advances with Biocytogen’s RenLite® transgenic mouse platform and proprietary linker/payload technologies at the forefront.

NEOK002 (previously known as ABL209) is a novel, bispecific ADC designed to simultaneously target two key cancer antigens—Epidermal Growth Factor Receptor (EGFR), a key oncogenic driver in multiple tumor types, and Mucin-1 (MUC1), a tumor-associated antigen characterized by aberrant glycosylation and overexpression.

Recent advances in antibody-drug conjugate (ADC) technology have enabled the development of highly potent, tumor-targeted therapeutics with improved efficacy and safety. Sutro Biopharma, leveraging its site-specific and cell-free protein synthesis platform, has reported robust preclinical data for its pipeline of next-generation ADCs at the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026.

Recent Advances in the Clinical Development of First- and Best-in-Class Antibody-Drug Conjugates: Pipeline Update from Adcendo

ZW191: A Next-Generation FRα-Targeted ADC Demonstrates Promising Efficacy and Safety in Advanced Solid Tumors

At the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA., new preclinical data will be presented for three proprietary antibody-drug conjugate (ADC) assets—CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC)—being developed by CStone Pharmaceuticals.

Patients treated with QLS5132, a novel antibody-drug conjugate (ADC) developed by Qilu Pharmaceutical Co. experienced clinical benefit. This conclusion is based on results from a phase 1 clinical study presented at the annual meeting of the American Association for Cancer Research, held April 17 - 22. 2026, in San Diego Ca.

B7-H4 (also known as B7 homolog 4, B7S1, or VTCN1) is an immunoregulatory ligand in the B7-CD28 family, notable for its overexpression in multiple tumor types, including breast, ovarian, uterine, and lung cancers. B7-H4 suppresses T-cell effector functions, including inflammatory cytokine production and cytolytic activity, and promotes the polarisation of naïve CD4 T-cells into induced Tregs, invasion, and metastasis, correlating with poor prognosis in advanced tumors. Its restricted expression in normal tissues and tumor-promoting roles make B7-H4 an attractive target for tumor-selective therapies such as antibody-drug conjugates (ADCs). B7-H4 has attracted credible attention from drug developers because it is highly expressed in immune 'cold' tumors, in which PD-1 and PD-L1 are minimally expressed, making these tumors unresponsive to most currently used immunotherapies.